Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Telehealth providers in Montana

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Telehealth prescribing is allowed in Montana, including asynchronous care. What Montana requires of telehealth prescribers and pharmacies, plus listings with their verification status.

Montana at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Telehealth providers serving Montana

Bodybuilding Peptides

Sponsored

Prescription peptides through an online assessment and a licensed provider review, shipped from a licensed U.S. compounding pharmacy.

Telehealth provider · 17 products · partner lists from $172 a month · Says it serves Montana (not yet confirmed)

  • Prescription only, no research-use-only sales
  • Public cancellation and refund policy

We may earn a commission from these links.

Telehealth prescribing rules in Montana

MCA 37-2-305 lets health care providers licensed in Montana provide services through telehealth when it is appropriate for the service, meets the standard of care, and complies with the licensing board's rules. It defines telehealth as audio, video, or other telecommunications technology, including audio-only communication, over a secure connection, and excludes fax or electronic messaging alone. The medical practice act, MCA 37-3-102, defines telemedicine to include store-and-forward technology, which covers information stored and reviewed later without the patient present in real time, and excludes e-mail, instant messaging conversations, and fax. Under Board of Medical Examiners rule ARM 24.156.813, a provider-patient relationship may be established by an in-person examination when the standard of care requires one, by consultation with a provider who has a documented relationship with the patient, or through telemedicine when the standard of care does not require an in-person encounter. The rule text was confirmed on the Cornell Legal Information Institute copy because the official page did not display it. The licensee must verify the patient's identity and obtain a sufficient medical history before prescribing. The prescriber must hold a Montana license under MCA 37-2-305. Montana law does not say whether a static questionnaire alone is enough. None of the peptides in this database are controlled substances. This record classifies asynchronous prescribing as allowed because the Board's rule lets the relationship be formed through telemedicine and the statute defines telemedicine to include store-and-forward technology with no real-time visit required. A service delivered only by e-mail, instant messaging, or electronic messaging alone is outside these definitions. [2] [3] [4]

Compounded GLP-1 access in Montana

Rural Montana patients often rely on mail order; any out-of-state pharmacy mailing compounded GLP-1s into Montana must be registered as an out-of-state mail order pharmacy under MCA 37-7-703. [5] [11]

Research use only sellers in Montana

The Montana Food, Drug, and Cosmetic Act (MCA Title 50, chapter 31) prohibits selling adulterated or misbranded drugs, and MCA Title 37, chapter 7 restricts dispensing of prescription drugs to licensed pharmacies. [1] [5] [9] [12]

How to check a telehealth provider in Montana

  1. Confirm the prescriber is licensed or registered to treat patients located in Montana; the telehealth rules above explain what Montana requires. [2] [3] [4]
  2. Ask which pharmacy will fill the prescription and check it in the Montana Board of Pharmacy (Department of Labor and Industry, Business Standards Division) license lookup. [1] [5] [6] [7] [8] [10]
  3. Get the full price in writing first: consult fees, membership fees, and the medication itself.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Montana. [1] [5] [9] [12]

Common questions in Montana

Can I get a GLP-1 prescription in Montana through telehealth?

Yes, from a Montana-licensed prescriber. MCA 37-2-305 authorizes telehealth, including audio-only care, and Board rule ARM 24.156.813 lets a relationship be established through telemedicine when the standard of care does not require an in-person visit. Fax, e-mail, or instant messaging used by itself does not count as telehealth or telemedicine. Semaglutide and tirzepatide are not controlled substances. [2] [3] [4]

Does Montana count a phone call as telehealth?

Yes. Montana's statutory definition of telehealth expressly includes audio-only communication over a secure connection, though the prescriber must still meet the standard of care for the condition being treated. [2]

Can an out-of-state pharmacy mail compounded peptides to me in Montana?

Only if it is registered with the Montana Board of Pharmacy as an out-of-state mail order pharmacy under MCA 37-7-703, which requires a home-state good-standing certificate and a named pharmacist in charge of Montana dispensing. [5] [6]

All peptide legal questions for Montana

Sources

  1. [1]Montana Board of Pharmacy
  2. [2]MCA 37-2-305, Telehealth services, rulemaking authority
  3. [3]MCA 37-3-102, Definitions (practice of medicine, store-and-forward technology, telemedicine)
  4. [4]ARM 24.156.813, Practice requirements for physicians and physician assistants using telemedicine (official site; rule text confirmed on the Cornell LII copy)
  5. [5]MCA 37-7-703, Out-of-state mail order pharmacy registration requirements
  6. [6]ARM 24.174.1001, Registration of out-of-state mail service pharmacies
  7. [7]ARM 24.174.841, Sterile products
  8. [8]Montana Board of Pharmacy, MAR Notice No. 2026-131, proposed amendment of ARM 24.174.841 and adoption of compounding rules
  9. [9]MCA Title 50, chapter 31, Food, drugs, and cosmetics
  10. [10]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  11. [11]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  12. [12]21 U.S.C. 331, Prohibited acts